Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 5/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.44 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.44 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502274 | 0.94 | AVPR1A (0.45) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL6585299 | 0.88 | OXTR (0.40) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL2500309 | 0.87 | AVPR1B (0.47) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL6581793 | 0.86 | AVPR1B (0.46) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL6582612 | 0.85 | OXTR (0.39) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL6947175 | 0.84 | POLB (0.42) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL2497562 | 0.84 | OXTR (0.42) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL2499338 | 0.84 | AVPR1A (0.52) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL2500497 | 0.84 | AVPR1A (0.52) | OXTRAVPR1AAVPR1BAVPR2GPR65 | |
| SCHEMBL2494759 | 0.84 | AVPR1A (0.45) | OXTRAVPR1AAVPR1BAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | OXTR 9/4885AVPR1A 3/4885AVPR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.